The Coverage Tax: London’s Unseen Small-Caps and the Price of Silence

For a London-listed company outside the FTSE 100, silence has a price. It appears in the spread, in the absence of a consensus forecast, in the discount at which the shares change hands and in the terms a board is offered when it returns to market for capital. The research gap in the UK small- and mid-cap market is not a niche complaint about broker economics. It is a structural feature of the market that behaves like a hidden tax on being listed.

The arithmetic of neglect

Equity research is a fixed-cost public good with a private revenue model. An analyst, compliance oversight, distribution and the sales effort required to place an idea all cost money before a single client pays for the note. In a market where dealing commissions once subsidised that bundle, the cost was spread across a large pool of trades and the marginal covered company could be quite small. After the separation of research from execution, the same activity must be paid for more directly, by a narrower set of asset managers who are themselves under pressure on costs and on the allocation of attention.

The result is concentration. Coverage clusters around the largest, most liquid names, where trading revenues and client demand justify the expense. Below that line, a company may retain one broker, a corporate adviser and an in-house investor-relations function, but no independent analyst willing to publish a forecast. The direction of travel is not seriously disputed even if the precise count of uncovered companies is contested. The consequences are observable: wider spreads, thinner order books, fewer institutional holders and a valuation that reflects uncertainty rather than a considered view of the business.

This is the coverage tax. It is not levied by a regulator or a exchange; it is levied by the market’s inability to see. A company that is not followed is not merely less popular. It is less legible to the capital-allocation process that decides whether a UK equity mandate should own it at all.

What unbundling changed

MiFID II’s inducements rules, applied in the UK from January 2018, forced asset managers to separate payment for research from payment for execution. The policy intention was sound: investors should know what they are paying for, and fund managers should not be able to dress up research as a free by-product of dealing. The transparency gain was real. The distributional consequence was less examined. By making research an explicit cost centre, the rules accelerated a retreat from broad, low-revenue coverage towards high-conviction names that could justify the subscription.

That shift coincided with a long period of consolidation among UK brokers and a squeeze on small-cap allocations within UK equity funds. Independent research houses have emerged, but subscription models are difficult to scale when the largest clients can internalise research and the smallest cannot afford it. Issuer-sponsored research has expanded into the space, often providing useful information, but it is not the same product as independent, adversarial analysis. The market has not so much lost research as redistributed it towards those who can pay directly, whether through commissions, subscriptions or corporate budgets.

The 2026 pooling debate

The policy argument in 2026 is less about reversing unbundling than about designing a conduit. A UK research pooling mechanism, whether through a sanctioned platform, a voluntary levy or a revised payment optionality, is being discussed as a way to widen coverage without returning to the opacity of bundled commissions. The appeal is obvious: if asset managers can pool a small charge to fund independent coverage of the market’s lower tiers, the fixed-cost problem is shared and the free-rider problem is reduced.

The difficulty is governance. Any pool must decide who sits on its board, how coverage is commissioned, how access is priced and how the largest managers are prevented from shaping the research agenda towards their own holdings. A pool that simply recreates the old broker hierarchy with a new funding line would fail the test. A pool that is too thinly funded would produce reports that no one reads. The policy debate is therefore not a technical question about payment mechanics. It is a question about whether the UK market can create a credible institution for the production of independent small-cap analysis.

Issuer-paid research: read the label

When a company’s only coverage is paid for by the company itself, investors should read the disclosure before they read the note. Issuer-sponsored research can be informative and can fill a genuine gap, particularly for companies that are too small for a broker’s published list. But it is not independent research in the ordinary sense. The analyst’s remuneration, the distribution arrangements and the absence of a sell recommendation are all part of the product.

The practical test is not whether the report is paid for but whether the investor can distinguish information from advocacy. Are the forecasts consistent with the company’s own guidance? Does the note carry a clear sponsor disclosure? Is there any evidence of sceptical scrutiny, or only a valuation bridge to a higher share price? Paid research can reduce ignorance; it cannot manufacture the adversarial pressure that independent coverage provides. The market’s verdict is usually visible in the spread and in the discount at which such companies trade.

What investors should watch

For portfolio managers, the first signal is the number and identity of independent analysts covering a name, not the number of notes in the inbox. Consensus dispersion matters more than consensus itself: a single forecast is a data point, not a market view. Liquidity should be measured in depth as well as in the headline spread, because a narrow quote on a small order is not the same as a tradeable market. Mandate eligibility follows coverage: index inclusion and fund mandates often depend on a minimum level of research and liquidity that an uncovered company cannot meet.

For boards, coverage is capital-markets infrastructure. It affects the cost of equity, the terms of a placing and the vulnerability of the register to an opportunistic bid. A company that is unseen is not merely undervalued; it is under-scrutinised, and that is a governance issue as much as a valuation one.

The 2026 pooling debate may improve the supply of research at the margin. It will not abolish the coverage tax on its own. Being unseen is not a neutral state in a public market. It is a discount, and someone always pays it.